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Background: Quantitative ultrasound bone densitometry (QUBD) is a new method to assess bone mineral density and bone
microarchitecture. Corticosteroid (CS) therapy may diminish bone mass, alter bone quality and may influence growth hormone (GH)
secretion and bone metabolism markers. Therefore, the aim of this study was to evaluate the effects of long-term therapy with inhaled CSs
(ICSs) on structural bone characteristics and their correlations with GH secretion and bone markers in asthmatic patients.
Methods: In a cross-sectional study, we enrolled 60 adult patients with mild to moderate persistent asthma: 22 on chronic (N1 year) ICS
therapy, 10 naive to ICSs treatment and 28 healthy control subjects. The groups were matched for age and BMI. Each subject underwent to
QUBD at the phalanxes to assess bone microarchitecture by ultrasound bone profile index (UBPI), bone density by amplitude-dependent
speed of sound (AdSos); test with GH-releasing hormone (GHRH) injection with calculation of peak GH and the Δ GH (peak GH–basal
GH); and hormonal and bone markers measurements.
Results: Asthmatics treated with long-term ICS therapy showed a lower UBPI (P b 0.01) compared to controls (49.8 ± 19.3 vs. 77.0 ± 10.1,
respectively) and to asthmatics never taking ICSs (73.2 ± 9.6). In ICS-treated asthmatics, ΔGH and GH-peak showed a significant correlation
with UBPI. A significant difference was observed comparing asthmatics treated with ICSs to controls and asthmatics naive to ICSs in GH
response to GHRH iv bolus. Serum osteocalcin was significantly reduced in asthmatic patients treated with ICSs.
Conclusions: In asthmatic patients, long-term ICSs treatment produces negative effects on bone quality assessed by QUBD, and such effects
are associated to an impaired GH secretion.
© 2005 Elsevier Inc. All rights reserved.Keywords: Quantitative bone ultrasound densitometry; Asthma inhaled corticosteroids; Growth hormoneIntroduction
Quantitative ultrasound bone densitometry (QUBD) is a
method to measure bone tissue in order to detect osteopo-
rosis [1,2], it provides information about the bone structure
and elasticity and not only about the bone mineral density
(BMD) [3,4]. The human phalanx consists of both trabecular
and cortical bone, a structure similar as vertebrae and hips.
The ability of QUBD at the phalanxes to identify patients at
risk of fragility fractures of the spine is accepted [5–7]. A⁎ Corresponding author. Fax: +39 030 396011.
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doi:10.1016/j.bone.2005.07.002recent study has demonstrated that QUBD at hand phalanxes
predicts vertebral fractures as effectively as BMD [8]. In
corticosteroid (CS)-treated patients, bone quality may be
more affected than bone mineral density (BMD) as the
frequency of vertebral fractures in these patients is reported
higher than expected for their BMD [9,10]. Therefore,
QUBD has been proposed as an effective method to evaluate
and to monitor bone alterations during CS therapy [11,12].
Inhaled CSs (ICSs) are recommended as the first-line
choice of anti-inflammatory drugs in the management of
asthma, and, currently, they have a widespread use [13]. ICSs
may cause dose-related systemic effects [14] affecting adrenal
and growth hormone axis and bone metabolism [15–17].
Table 1






Number 22 10 28
Sex M/F 10/12 4/6 13/15 0.95 a
Age (years)
Mean ± SD 50.8 ± 7.0 47.1 ± 5.2 48.5 ± 8.8 0.56
BMI (kg/m2)
Mean ± SD 26.5 ± 6.0 25.1 ± 4.0 25.0 ± 4.0 0.25
Smoking history
Smoker 0 0 0 0.83 a
120 M. Malerba et al. / Bone 38 (2006) 119–124Osteoporosis is a potential but common side-effect of chronic
treatment with CSs, however, the mechanisms by which CSs
lead to a reduction in bone mass are complex, involving both
direct and indirect effects on the remodeling cycle [18,19].
The reduction of growth hormone (GH) secretion observed
during CS treatment seems to be relevant to induce bone loss
[20–22]. Therefore, the aim of this study was to evaluate the
effects of long-term therapy with ICSs on structural bone
characteristics and their association with GH secretion and
bone markers in asthmatic patients, in comparison with
asthmatics who never used ICSs and control subjects.Ex-smoker 10 4 10
Never smoker 12 6 18
FEV1 (% pred)
Mean ± SD 91.6 ± 5.5 89.3 ± 5.3 94.5 ± 3.5 0.07
UBPI
Mean ± SD 49.8 ± 19.3 b 73.2 ± 9.6 77.0 ± 10.1 0.001
(CI95%) (40.9/58.6) (66.2/80.1) (72.8/81.1)
AdSos Z score
Mean ± SD −0.2 ± 1.4 0.09 ± 0.9 0.2 ± 1.2 0.364
(CI95%) (−0.8/0.4) (−0.5/0.7) (−0.2/0.8)
AdSos T score
Mean ± SD −1.1 ± 1.2 −0.1 ± 1.1 −0.7 ± 1.1 0.06
(CI95%) (−1.7/−0.6) (−1.2/0.9) (−1.2/−0.3)
BMI: body mass index.
FEV1: forced expiratory volume in the first second.
UBPI: ultrasound bone profile index.
AdSos: amplitude-dependent speed of sound.
a Analysis performed by χ2.
b Asthmatics on ICS vs. asthmatics naive ICS and controls (Bonferroni
correction).Patients and methods
Patients
In a cross-sectional study, we enrolled 60 consecutive
adult patients with mild to moderate persistent asthma,
diagnosed according to National Institutes of Health (NIH)
criteria [13], 22 on chronic (N1 year) ICS therapy (12
female, 10 male; age: 50.0 ± 7.0 years.; BMI: 26.5 ± 6.0
kg/m2) and 10 naive to ICS treatment (6 female, 4 male;
age 47.1 ± 5.2 years; BMI: 25.1 ± 4.0 kg/m2), who were
referred to our Pulmonary Function Laboratory in the
Department of Internal Medicine (Brescia, Italy). We
enrolled 28 healthy control subjects (15 female, 13 male;
age 48.5 ± 8.8 years; BMI: 25.0 ± 4.0 kg/m2).
Exclusion criteria were the following: age b18 years and
N65 years, BMI N30 kg/m2 and b20 kg/m2, diseases
potentially interfering with the study (i.e. endocrine disease,
hepatic or renal failure, premature or surgical menopause
without replacement hormonal therapy), treatment with other
drugs known to influence either GH secretion or bone
metabolism. Moreover, asthmatics with sedentary lifestyle,
with excessive alcohol intake, with history of a course of
systemic CSs in the past 6 months or more than two courses
(no longer than 7 days) ever and more than 10 inhalers of a
nasal CS or 10 prescriptions of dermal CS ever were
excluded. At the time of inclusion, all the asthmatic patients
were in a stable condition and free from respiratory
exacerbations. The severity of asthma was classified in the
groups studied by clinical features and pulmonary function
tests before treatment [13]. The study protocol was approved
by the local Ethics Board, and all subjects gave their written
informed consent to participate, and the study was conducted
in accordance with the Helsinki Declaration.
Demographic and functional characteristics of the
asthmatic patients and controls are reported in Table 1.
Study protocol
Clinical assessment
At the beginning, each subject completed a questionnaire
and performed pulmonary function tests. The questionnaire
asked about current and previous drug treatment, history ofasthma, smoking and alcohol intake and physical activity.
Exercise tolerance was not specifically assessed, however,
no difference was found in the questionnaire concerning
physical activity between asthmatics on ICSs and asthmatics
ICS naive. Women were asked about menstrual history or
premature or surgical menopause. All ICS-treated patients
were on the lowest possible maintenance dose as a result of
previous attempts of dose stepping down. The asthmatic
patients taking ICSs who were included in the study used a
standard dosage of either budesonide or fluticasone propi-
onate. The mean daily dose of budesonide administered with
a turbohaler was 780 ± 290 mcg in 13 patients, while the
mean daily dose of fluticasone propionate administered with
a metered dose inhaler was 695 ± 380 mcg in 9 patients.
Given the relatively small number of asthmatics treated with
ICSs and the almost equipotent mean dose of budesonide and
fluticasone propionate they used, these patients were
analyzed as a single group.
Quantitative ultrasound bone densitometry (QUBD)
QUBD measurements were taken at the fingers of the
nondominant hand by the DBM sonic 1200 (Igea, Carpi, Mo,
Italy). This instrument has an electronic caliper with arms that
have transmitting and receiving probes that work at a
frequency of 1.25 MHz. The device measures the ampli-
tude-dependent speed of sound (AdSos) through the bone by
121M. Malerba et al. / Bone 38 (2006) 119–124positioning the probes of the electronic caliper on the medial
and lateral sites of the distal metaphysis of the proximal
phalanx of the last four fingers. The averaged values of the
four measurements are given as the examination result and
expressed in m s−1. The Sos is calculated by measuring the
phalanx thickness (using a high-precision 10-μm electronic
potentiometer contained in the positioning caliper) and
dividing it by the flight time. The flight time is the time
elapsed from the generation of the pulse to the instant when
the signal received reaches a predetermined minimum
amplitude value (2 mV) for the first time. The same device
calculates the ultrasound bone profile index (UBPI), which is
an index calculated from the ultrasound (US) graphic trace,
giving a quantitative evaluation of the US signal character-
istics carrying an important amount of information on bone
quality. In detail, the following parameters on each graphic
trace were considered: fast wave amplitude (FWA: mV),
dynamics of the ultrasound signal (SDy: mV/mvs2), time
interval between the first received signal and the speed value
of 1700m/s (time frame [TF]: mcs), signal energy normalized
(SE: mV2 mcs), maximum signal amplitude in the TF (UPA:
mV). As previously reported, calculation of UBPI was based
on the following mathematical equation: UBPI =
−(−0.0018 × SDy −0.0560 × FWA − 1.1467 × TF + 3.0300).
Calibration of the device has been given using the dedicated
Plexiglas phantom according to manufacturer's instructions.
For QUBD measurement, in vivo coefficient of variation
(CV) was estimated in twenty volunteers by three short-term
QUBD repeated measurements taken by two operators over a
period of 7 days. For UBPI, we found 3.1% CV intraoperator
and 3.35% CV interoperator; for AdSos in the same data set,
we found 0.85% CV intraoperator and 0.95% CV inter-
operator. These data are in line with what has been previously
reported [6] Reference values for calculating Z score (SD
decrease from age-matched normals) and T score (SD
decrease below young normal value) were obtained from
Italian population-based studies [23–25]. Measurements
were performed using US contact gel.
Hormonal and bone markers
Hormonal and biochemical evaluations were performed
as previously described [26]. Briefly, subjects underwent
testing with IV bolus (1 μg/kg) injection of human GH-
releasing hormone (GHRH) (Geref, Serono, Italy), and
samples of GH (IRMA assay, Nichols Institute, USA,
Allegro hGH, Nichols Institute, San Juan Capistrano, CA)
were taken before and after GHRH administration to
obtain values for peak GH (the highest GH value observed
after stimulus with GHRH) and ΔGH [peak GH − (baseline
GH + GH at time 0) / 2]. At baseline samples of serum,
insulin-like growth factor 1 (IGF-1) (IRMA assay, Nichols
Institute, USA, after acid–ethanol extraction) and blood–
urine were collected for bone turnover markers and to
measure serum and urine cortisol. Serum osteocalcin as
marker of bone formation was assessed by radioimmunoas-
say (Nichols Institute, USA), and urinary deoxypyridinolineas marker of bone resorption was assessed by ELISA
(corrected for urinary creatinine concentration).
Lung function measurements
Dynamic lung volumes were measured using a spirometer
(CAD/Net system 1070, MCG, St. Paul, Minnesota USA) in
accordance with the American Thoracic Society (ATS)
standard procedure [27]. In subjects with forced expiratory
volume in the first second (FEV1) ≤70% of forced vital
capacity (FVC), two puffs of bronchodilator (albuterol: 200
mcg) were administered with a metered dose inhaler (MDI),
and FVC test was repeated after 20 min. A significant
bronchodilator response was defined as an increase of 12%
and 200 ml in respect to the baseline FEV1.
Statistical analysis
Data are expressed as mean and standard deviation (SD)
or 95% confidence intervals (CI95%). A normality of data
distribution was established using Kolmogorov–Smirnov
test. In case of normal data distribution, significant
differences among groups were performed by one-way
analysis of variance (ANOVA) with Bonferroni post-hoc
analysis. Nonparametric test (Kruskal–Wallis test) was used
when appropriate. Linear regression model was used to study
the relationship between the considered variables. Chi-
square analysis was used to test categorical variables. A P
value of b0.05 was considered to be statistically significant.Results
The data of subjects studied are reported in Table 1. No
significant difference in anthropometric parameters was
observed among the 3 groups studied. Median duration of
treatment in the asthmatic patients taking ICSs was 38.5
months (range: 20–58 months).
Ultrasound bone profile index (UBPI) and correlations with
hormonal and bone marker parameters
In ICS-treated asthmatic patients, UBPI was signifi-
cantly lower (P b 0.01) compared to controls (49.8 ± 19.3
vs. 77.0 ± 10.1, respectively) and to asthmatic patients
naive to ICSs (73.2 ± 9.6) (Fig. 1). No differences were
observed in AdSos values among the groups studied. A
significant correlation between structural characteristics of
bone microarchitecture measured by UBPI, ΔGH and GH
peak was observed (R = 0.4; P b 0.05) in ICS-treated
asthmatic patients (Fig. 2). UBPI or AdSos values did
not show a significant correlation with serum osteocalcin
(P = 0.069) in the group of asthmatics taking ICSs.
GH secretion
Mean GH peak and ΔGH in asthmatic patients treated
with ICSs were lower (4.0 ± 2.1 ng/ml; 1.9 ± 3.0 ng/ml,
Fig. 1. Individual values of ultrasound bone profile index (UBPI) in the three
groups studied. *P b 0.1.
122 M. Malerba et al. / Bone 38 (2006) 119–124respectively) as compared to mean GH peak and ΔGH both
in controls (19.0 ± 12.7 ng/ml: P b 0.01; 13.2 ± 7.5 ng/ml:
P b 0.01 respectively) and in asthmatics naive to ICSs
(16.9 ± 15.1 ng/ml; P = 0.04; 12.4 ± 7.6 ng/ml; P = 0.033
respectively).
Biochemical data
Serum osteocalcin levels were significantly reduced in
the group of asthmatic patients on chronic ICS treatment
(6.4 ± 2.5 ng/ml) when compared with controls (17.6 ± 5.5Fig. 2. Correlation between ultrasound bone profile index (UBPI) values, growth
inhaled corticosteroid therapy.ng/ml; P b 0.01), and with asthmatics who never used ICS
treatment (17.4 ± 4.5 ng/ml; P b 0.01), showing a significant
correlation with values of GH peak (r2 = 0.34, P = 0.007).
Baseline IGF1 values were similar in all groups. ICS
treatment had no significant effects on serum calcium, serum
phosphorus, urinary calcium, urinary levels of deoxypyr-
idinoline and urinary and serum levels of cortisol. No
statistical difference in any variable considered was found
between asthmatics naive to ICSs and the control group.Discussion
The present study shows that, in asthmatic patients
receiving long-term treatment with ICSs, the bone quality
and osteocalcin levels are significantly reduced in compar-
ison with asthmatic patients who have never been treated
with ICSs and with control subjects. Moreover, these
negative bone effects are associated with an impairment of
GH secretion after GHRH stimuli. Our data demonstrate that,
in asthmatics during long-term ICS treatment, the UBPI
values are reduced compared to asthmatics not taking ICSs
and control subjects, while AdSos values do not change
among three groups. This latter finding can be explained by
the fact that UBPI is a parameter correlated to bone quality
and giving information about bone microarchitecture
(density and disposition of trabeculae) [3], while AdSos is
a more direct index of BMD. Bone loss due to ICSs differs
from that of postmenopausal osteoporosis in terms of bone
structure. In fact, CSs affect horizontal and vertical
trabeculae, while, in postmenopausal osteoporosis, only
horizontal structures are damaged [12]. According with this
observation, Soballa showed that AdSos and UBPI signif-
icantly discriminated healthy subjects from patients withhormone (GH) peak and ΔGH in asthmatic patients treated with long-term
123M. Malerba et al. / Bone 38 (2006) 119–124osteoporosis and from patients receiving CS treatment [28].
Finally, our data may explain the results of previous studies
that fail to find a difference of BMD by dual photon X-ray
absorptiometry (DEXA) in healthy people and asthmatics
under ICS treatment [29,30], suggesting that in these patients
the bone quality is more affected than bone mass, as
demonstrated in patients during long-term CS systemic
treatment [11].
A significant inhibition in GH secretion after GHRH in
asthmatic patients under ICSs compared to asthmatics ICS
naive and controls has been reported in our recent study [26],
suggesting that long-term ICS treatment is able to influence
GH axis in asthmatic patients as previously demonstrated in
oral CS-treated patients [31]. GH is important in the
regulation of bone metabolism by direct interaction with
GH receptors on osteoblasts [32] Therefore, the correlation
found between UBPI values and alteration of GH secretion
after GHRH stimuli might partly explain the bone loss
observed during long-term ICS treatment. Such hypothesis is
supported by the observation that in asthmatic patients taking
ICS the inhibition of GH secretion is significantly correlated
with a reduction of osteocalcin levels, a marker of bone
formation. A recent systematic review [33] showed a
reduction of osteocalcin serum levels in the asthmatic
patients taking ICSs. In the present study this reduction
was associated with the decrease (not statistically significant)
of UBPI values, suggesting a bone loss mechanism acting
mainly by reducing bone formation. Our observation may be
consistent also with other mechanisms recently described for
glucocorticoid-induced reduction of bone formation. In fact,
glucocorticoids promote the apoptosis of osteoblasts and
osteocytes, and this contributes to decreased number of
mature osteoblasts [34]. Moreover, it has been recently
reported that glucocorticoids may be involved in a shift of
cellular differentiation away from osteoblasts and toward
adipocytes [35,36].
Limitations of the study are the relative small number of
subjects studied and the lack of BMD measurements by
DEXA. Comparisons of our results with those reported by
other authors are difficult because of different methodology
used in other studies and the lack of studies in asthmatics
treated with ICSs evaluated by QUBD. A recent paper [37]
has assessed the bone status by QUBD in asthmatic male
patients under long-term oral CS treatment, showing that
QUBD is able to discriminate between control subjects and
male asthmatics under CSs and also the presence of a bone
loss in these patients. It is noteworthy that present study
shows similar findings in asthmatic patients taking CSs only
by the inhaled route indicating the potential risk of
osteoporosis following a chronic treatment with ICSs.
Therefore, despite the limitations abovementioned, our
study can have practical implications since UBPI abnormal-
ities should lead clinicians to the suspect of an increased risk
of fracture to initiate an anti-osteoporotic treatment or
eventually to modify the anti-asthmatic therapy (lower dose,
change the treatment).In conclusion, the results of our study indicate that the
long-term administration of ICSs significantly reduces bone
quality as assessed by QUBD at phalanxes and marker of
bone formation in adult asthmatic patients, and such effects
are associated with inhibited secretion of GH after GHRH
stimuli. These data suggest that both the evaluation of bone
microarchitectural structure by QUBD and the hypotha-
lamic–pituitary–GH axis may be useful in the follow-up of
asthmatic patients who are receiving long-term treatment
with ICSs. However, further prospective studies are needed
to confirm these results and also to evaluate whether in
some patients is reasonable to discontinue chronic treat-
ment with ICSs and/or to prescribe treatment to prevent
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